Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Assets: 2020-2024

Historic Current Assets for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $789.0 million.

  • Apellis Pharmaceuticals' Current Assets rose 18.80% to $990.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $990.7 million, marking a year-over-year increase of 18.80%. This contributed to the annual value of $789.0 million for FY2024, which is 2.95% up from last year.
  • Apellis Pharmaceuticals' Current Assets amounted to $789.0 million in FY2024, which was up 2.95% from $766.3 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Current Assets ranged from a high of $917.2 million in FY2020 and a low of $719.5 million during FY2022.
  • In the last 3 years, Apellis Pharmaceuticals' Current Assets had a median value of $766.3 million in 2023 and averaged $758.3 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Current Assets dropped by 12.68% in 2022, and later increased by 6.51% in 2023.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Current Assets stood at $917.2 million in 2020, then declined by 10.16% to $824.0 million in 2021, then dropped by 12.68% to $719.5 million in 2022, then rose by 6.51% to $766.3 million in 2023, then grew by 2.95% to $789.0 million in 2024.